Beta Bionics (BBNX) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company focused on improving diabetes management for insulin-requiring patients using adaptive closed-loop algorithms.

• Flagship product, the iLet Bionic Pancreas, is FDA-cleared for type 1 diabetes (T1D) in patients six years and older, automating all insulin dosing without carb counting.

• iLet integrates with leading CGMs (Dexcom G6/G7, Abbott FreeStyle Libre 3 Plus) and is designed for ease of use, requiring only body weight for initialization.

• Business model includes device sales and recurring revenue from single-use products (cartridges, infusion sets), with a multi-channel reimbursement strategy (DME and PBP).

• Pipeline includes a patch pump and a bihormonal iLet (insulin and glucagon), with plans to expand into insulin-dependent type 2 diabetes (T2D).

Financial performance and metrics

• Revenue grew from $12.0M in 2023 to $44.7M for the nine months ended September 30, 2024; Q3 2024 revenue was $16.7M, up from $3.1M in Q3 2023.

• Net losses were $44.1M in 2023 and $36.6M for the nine months ended September 30, 2024; accumulated deficit reached $278.6M as of September 30, 2024.

• Gross margin improved to 54% for the nine months ended September 30, 2024, up from 34% in the prior year period.

• Installed customer base grew to over 11,200 by September 30, 2024, with 67% of new patient starts coming from MDI users.

• As of December 31, 2024, cash, cash equivalents, and short-term investments were approximately $103.6M.

Use of proceeds and capital allocation

• Estimated net proceeds of $114.4M from the IPO and concurrent private placement at $15.00/share.

• Proceeds will fund: (i) development and regulatory submissions for the bihormonal iLet and glucagon product, (ii) development and manufacturing of the patch pump, and (iii) expansion of sales/manufacturing infrastructure, working capital, and general corporate purposes.

• Funds are expected to support operations through the first half of 2028.